Kusakabe K, Kawasaki Y
Department of Radiology, Tokyo Women's Medical College, Japan.
Radiat Med. 1987 Sep-Oct;5(5):175-9.
The purpose of this study was to apply a new radiopharmaceutical for thrombus imaging. Forty patients with thrombus, including 18 with aortic aneurysm and seven with graft replacement, were studied using the planar imaging technique. Thrombus imagings were obtained 6-96 hours after intravenous administration of 2 mCi of 67Ga-DFO-DAS-fibrinogen (67Ga-fibrinogen). The best images were achieved 48-96 hours after 67Ga-fibrinogen administration. Twenty-one of 40 patients with proven thrombus had positive planar images. A high positive ratio (83%) was obtained in patients with aortic aneurysm. In the remaining patients, the planar images were interpreted as showing no evidence of active thrombus formation of fibrinogen. These studies demonstrate the potential of 67Ga-fibrinogen for the noninvasive localization of active thrombi.
本研究的目的是应用一种新型放射性药物进行血栓成像。对40例血栓患者进行了研究,其中包括18例主动脉瘤患者和7例接受移植物置换的患者,采用平面成像技术。在静脉注射2毫居里的67Ga-DFO-DAS-纤维蛋白原(67Ga-纤维蛋白原)后6至96小时获得血栓图像。在注射67Ga-纤维蛋白原后48至96小时获得最佳图像。40例经证实有血栓的患者中,21例平面图像呈阳性。主动脉瘤患者的阳性率较高(83%)。在其余患者中,平面图像显示无纤维蛋白原活性血栓形成的迹象。这些研究证明了67Ga-纤维蛋白原在无创定位活性血栓方面的潜力。